Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 8929SC

8929SC 5 µg (With Carrier) $159.00
8929SF 5 µg (Carrier Free) $159.00
8929LC 25 µg (With Carrier) $459.00
8929LF 25 µg (Carrier Free) $459.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human M-CSF (hM-CSF) Glu33-Ser190 (Accession #P09603-3) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hM-CSF. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hM-CSF contains no "tags" and the nonglycosylated protein has a calculated MW of 18,403. DTT-reduced protein migrates as a 16-26 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 34-40 kDa protein. Heterogeneity in SDS PAGE is due to glycosylation. The expected amino-terminal EEVSE of recombinant hM-CSF was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hM-CSF was determined in a M-NFS-60 cell proliferation assay. The ED50 of each lot is between 0.5-2.0 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hM-CSF.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hM-CSF. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

Macrophage-colony stimulating factor (M-CSF) is produced by fibroblasts, endothelial cells, stromal cells, macrophages, osteoblasts and other cell types (1). M-CSF is required for growth and differentiation of monocytes and macrophages (1,2). M-CSF polarizes macrophages into the M2 phenotype where anti-inflammatory IL-10 is produced, rather than the M1 phenotype where inflammatory cytokines are produced. M-CSF also recruits monocytes and enhances angiogenesis by inducing VEGF production (1,2). M-CSF binds to its receptor (CSF1R); downstream signaling involves PI3K/Akt, ERK and STATs 1, 3, and 5 (1,3). An increase in M-CSF expression may contribute to cancer progression and a higher plasma M-CSF level is associated with rheumatoid arthritis (1,4,5).


1.  Hamilton, J.A. (2008) Nat Rev Immunol 8, 533-44.

2.  Curry, J.M. et al. (2008) PLoS One 3, e3405.

3.  Rioja, I. et al. (2008) Arthritis Rheum 58, 2257-67.

4.  Skrzypski, M. et al. (2008) Clin Cancer Res 14, 4794-9.

5.  Hamilton, J.A. (1997) J Leukoc Biol 62, 145-55.


Entrez-Gene Id 1435
Swiss-Prot Acc. P09603


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.